ID
12320
Description
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: End of Protocol Form
Keywords
Versions (3)
- 11/9/15 11/9/15 -
- 12/28/15 12/28/15 -
- 2/11/16 2/11/16 -
Uploaded on
November 9, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
End of Protocol Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26
End of Protocol Form
- StudyEvent: ODM
Description
Comments
Similar models
End of Protocol Form
- StudyEvent: ODM